Trevena is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System (CNS) conditions.
Our lead product candidate is oliceridine injection, a G protein-selective agonist at the mu-opioid receptor being developed for the management of moderate to severe acute pain in hospitals or other controlled clinical settings where intravenous, or IV, opioid therapy is warranted. We are also developing several other product candidates with the potential to address problems across a wide range of therapeutic areas, including migraine, opioid use disorder, and chronic pain.
Our history is rooted in strong science – Trevena was founded to translate Nobel Prize-winning research
At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet. We have used the biological processes of microorganisms for more than 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.
Modern biotechnology provides breakthrough products and technologies to combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes.
Currently, there are more than 250 biotechnology healthcare products and vaccines available to patients, many for previously untreatable diseases. More than 13.3 million farmers around the world use agricultural biotechnology to increase yields, prevent damage from insects and pests and reduce farming's impact on the environment. And more than 50 biorefineries are being built across North America to test and refine technologies to produce biofuels and chemicals from renewable biomass, which can help reduce greenhouse gas emissions.
In this section, we will provide periodic updates on key issues facing the advancement of science and the ability of researchers and entrepreneurs to deliver the latest medical and biological breakthroughs to people who need them around the world.
Today, more than 1.7 million Americans are employed in the biosciences across the U.S. These are good paying jobs that are focused on how we can use the latest developments in science and biology to create new medicines to treat some of the world’s most devastating diseases.
This is extremely satisfying and fulfilling work, but it can also be very challenging. As the Economist Magazine noted, “Creating new drugs through biotechnology is at the risky end of a business in which superhuman stamina and bottomless pockets are minimum requirements.”
That is why it is so important that our state and federal policymakers create laws and regulations that help spur medical innovation. The reality is that the only thing that can impede getting new cures and therapies to the patients relying on them is short-sighted policy proposals that stifle innovation and scare away investment. Entrepreneurs and investors need policy certainty to be successful at the incredibly difficult task of drug development, where more than 90% of endeavors fail.
These policies include:
To learn more, click here (PDF).
Copyright © Trevena, Inc.